-
摘要: 肾细胞癌（RCC）是泌尿系统常见的恶性肿瘤之一。分子靶向治疗是通过干预肿瘤细胞信号传导通路，抑制肿瘤的生长。相比于传统的细胞因子治疗手段，肾癌靶向治疗效果更好。但是目前对肾癌靶向治疗的预后仍缺乏有效判断手段，本文结合最新研究综述了RCC靶向治疗预后密切相关的影响因素研究现状及进展。Abstract: Renal cell carcinoma (RCC) is one of the most common malignant urinary tumors. Molecular targeted therapy is a way that can inhibit tumor growth by specific cellular pathway. Also, it is better than traditional cytokine therapy. However, effective ways for determing the outcome of targeted therapy are still insufficient. In this review, prognostic related factors of targeted therapy in renal cell carcinoma were summarized referred to the current study.
-
Key words:
- renal cell carcinoma /
- targeted therapy /
- prognosis
-
-
[1] Motzer R J, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma[J]. J Clin Oncol, 1999, 17(8):2530-2540.
[2] Belldegrun A S, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005):a benchmark for emerging targeted cancer therapies[J]. Cancer, 2008, 113(9):2457-2463.
[3] Escudier B, Eisen T, Stadler W M, et al. Sorafenib for treatment of renal cell carcinoma:Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial[J]. J Clin Oncol, 2009, 27(20):3312-3318.
[4] Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double-blind phase III trial[J]. Lancet, 2007, 370(9605):2103-2111.
[5] Motzer R J, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial[J]. Lancet, 2008, 372(9637):449-456.
[6] Motzer R J, Hutson T E, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(22):3584-3590.
[7] Suárez C, Morales R, Muñoz E, et al. Molecular basis for the treatment of renal cell carcinoma[J]. Clin Transl Oncol, 2010, 12(1):15-21.
[8] Mendel D B, Laird A D, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1):327-337.
[9] Ferrara N, Hillan K J, Gerber H P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5):391-400.
[10] Motzer R J, Rini B I, Bukowski R M, et al. Sunitinib in patients with metastatic renal cell carcinoma[J]. JAMA, 2006, 295(21):2516-2524.
[11] Motzer R J, Hutson T E, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2):115-124.
[12] Choueiri T K, Garcia J A, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. Cancer, 2007, 110(3):543-550.
[13] Han K S, Jung D C, Choi H J, et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy[J]. Cancer, 2010, 116(10):2332-2342.
[14] Schmidinger M, Vogl U M, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma:blessing or curse[J]? Cancer, 2011, 117(3):534-544.
[15] Rini B I, Cohen D P, Lu D R, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib[J]. J Natl Cancer Inst, 2011, 103(9):763-773.
[16] Eechoute K, van der Veldt A A, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension[J]. Clin Pharmacol Ther, 2012, 92(4):503-510.
[17] Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma:results from expanded access studies[J]. J Clin Oncol, 2008, 26(20):3469-3471; author reply 2471.
[18] Choueiri T K, Regan M M, Rosenberg J E, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy[J]. BJU Int, 2010, 106(6):772-778.
[19] Golshayan A R, George S, Heng D Y, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. J Clin Oncol, 2009, 27(2):235-241.
[20] Rink M, Chun F K, Robinson B, et al. Tissue-based molecular markers for renal cell carcinoma[J]. Minerva Urol Nefrol, 2011, 63(4):293-308.
[21] Deprimo S E, Bello C L, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma:modulation of VEGF and VEGF-related proteins[J]. J Transl Med, 2007, 5:32.
[22] Rini B I, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma:impact of patient characteristics and Von Hippel-Lindau gene status[J]. BJU Int, 2006, 98(4):756-762.
[23] Choueiri T K, Vaziri S A, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma[J]. J Urol, 2008, 180(3):860-865; discussion 865-866.
[24] Tsavachidou-Fenner D, Tannir N, Tamboli P, et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma[J]. Ann Oncol, 2010, 21(8):1599-1606.
[25] Peña C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma:Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial[J]. Clin Cancer Res, 2010, 16(19):4853-4863.
[26] Choueiri T K, Regan M M, Rosenberg J E, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy[J]. BJU Int, 2010, 106(6):772-778.
[27] Huang S, Houghton P J. Inhibitors of mammalian target of rapamycin as novel antitumor agents:from bench to clinic[J]. Curr Opin Investig Drugs, 2002, 3(2):295-304.
[28] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med, 2007, 356(22):2271-2281.
[29] Armstrong A J, George D J, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin[J]. J Clin Oncol, 2012, 30(27):3402-3407.
[30] Sun Y, Rha S, Lee SH, et al. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma[J]. Jpn J Clin Oncol, 2012, 42(9):836-844.
[31] Dutcher J P, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies[J]. Med Oncol, 2009, 26(2):202-209.
[32] Lin F, Zhang P L, Yang X J, et al. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas[J]. Ann Clin Lab Sci, 2006, 36(3):283-293.
[33] Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma[J]. Clin Genitourin Cancer, 2007, 5(6):379-385.
[34] Gordan J D, Lal P, Dondeti V R, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma[J]. Cancer Cell, 2008, 14(6):435-446.
-
计量
- 文章访问数: 110
- PDF下载数: 64
- 施引文献: 0
下载: